Milica Barac

Milica Barac

Auto-generated profile, based on publicly available information

Milica Barac

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MBMilica Barac
Milica Barac
SSSamantha Scaletty
Samantha Scaletty
LHLeslie C Hassett
Leslie C Hassett
ASAshley Stillwell
Ashley Stillwell
PCPaul Croarkin
Paul Croarkin
LDLiselotte N Dyrbye
Liselotte N Dyrbye
Background: The occupational burnout epidemic is a growing issue, and in the United States, up to 60% of medical students, residents, physicians, and registered nurses experience symptoms. Wearable technologies may provide an opportunity to predict the onset of burnout and other forms of distress using physiological markers. Objective: This study aims to identify physiological biomarkers of burnout, and establish what gaps are currently present in the use of wearable technologies for burnout prediction among health care professionals (HCPs). Methods: A comprehensive search of several databases was performed on June 7, 2022. No date limits were set for the search. The databases were Ovid: MEDLINE(R), Embase, Healthstar, APA PsycInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Science Core Collection via Clarivate Analytics, Scopus via Elsevier, EBSCOhost: Academic Search Premier, CINAHL with Full Text, and Business Source Premier. Studies observing anxiety, burnout, stress, and depression using a wearable device worn by an HCP were included, with HCP defined as medical students, residents, physicians, and nurses. Bias was assessed using the Newcastle Ottawa Quality Assessment Form for Cohort Studies. Results: The initial search yielded 505 papers, from which 10 (1.95%) studies were included in this review. The majority (n=9) used wrist-worn biosensors and described observational cohort studies (n=8), with a low risk of bias. While no physiological measures were reliably associated with burnout or anxiety, step count and time in bed were associated with depressive symptoms, and heart rate and heart rate variability were associated with acute stress. Studies were limited with long-term observations (eg, ≥12 months) and large sample sizes, with limited integration of wearable data with system-level information (eg, acuity) to predict burnout. Reporting standards were also insufficient, particularly in device adherence and sampling frequency used for physiological measurements. Conclusions: With wearables offering promise for digital health assessments of human functioning, it is possible to see wearables as a frontier for predicting burnout. Future digital health studies exploring the utility of wearable technologies for burnout prediction should address the limitations of data standardization and strategies to improve adherence and inclusivity in study participation.

5 September 2025 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MBMilica Barac
Milica Barac
CGCaroline Grant
Caroline Grant
RTRussell Toll
Russell Toll
TCThomas Carmody
Thomas Carmody
AMAbu Minhajuddin
Abu Minhajuddin
MTMadhukar Trivedi
Madhukar Trivedi
This report sought to employ multi-modal integration of pre-treatment brain (electroencephalogram, resting-state functional magnetic resonance imaging) and blood (immune and metabolic) biomarkers to facilitate causal inference-based treatment selection by virtue of establishing predictability of remission to multi-stage antidepressant treatment. Data from two stages of pharmacotherapy in the ‘Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression’ (EMBARC) study from participants with both brain and blood biomarkers were included (N = 197). Participants were initially randomized to sertraline or placebo (Stage 1), and depending on clinical response at week-8, their therapy in Stage 2 was either maintained or switched (to sertraline, if a non-responder to placebo, or to bupropion, if a non-responder to sertraline). Three readily accessible clinical features combined with 15 multi-modal features associated with baseline depression severity predicted stage 2 remission with an AUC of 0.74, 0.71, and 0.73 for sertraline, bupropion, and placebo treatment respectively. Propensity score-matching (causal inference) was conducted across Stage 2 treatment arms, and the same features were used to build an unsupervised model to produce the probability of remission to the given Stage 2 treatment (as factual outcome), as well as the alternative treatment not given (as counter factual). While the accuracy of observed outcomes across treatment arms was 82%, the accuracies of predicted counterfactual (unobserved) outcomes warrant future prospective studies. 16 weeks and associated biomarker-based prediction of counterfactuals suggest that the selected markers are highly sensitive features for guiding antidepressant treatment selection.

24 June 2023 in JMIR Preprints
Verified
Preprint
Open access
MBMilica Barac
Milica Barac
SSSamantha Scaletty
Samantha Scaletty
LHLeslie C Hassett
Leslie C Hassett
ASAshley Stillwell
Ashley Stillwell
PCPaul Croarkin
Paul Croarkin
LDLiselotte N Dyrbye
Liselotte N Dyrbye
BACKGROUND The occupational burnout epidemic is a growing issue, and in the United States, up to 60% of medical students, residents, physicians, and registered nurses experience symptoms. Wearable technologies may provide an opportunity to predict the onset of burnout and other forms of distress using physiological markers. OBJECTIVE This study aims to identify physiological biomarkers of burnout, and establish what gaps are currently present in the use of wearable technologies for burnout prediction among health care professionals (HCPs). METHODS A comprehensive search of several databases was performed on June 7, 2022. No date limits were set for the search. The databases were Ovid: MEDLINE(R), Embase, Healthstar, APA PsycInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Science Core Collection via Clarivate Analytics, Scopus via Elsevier, EBSCOhost: Academic Search Premier, CINAHL with Full Text, and Business Source Premier. Studies observing anxiety, burnout, stress, and depression using a wearable device worn by an HCP were included, with HCP defined as medical students, residents, physicians, and nurses. Bias was assessed using the Newcastle Ottawa Quality Assessment Form for Cohort Studies. RESULTS The initial search yielded 505 papers, from which 10 (1.95%) studies were included in this review. The majority (n=9) used wrist-worn biosensors and described observational cohort studies (n=8), with a low risk of bias. While no physiological measures were reliably associated with burnout or anxiety, step count and time in bed were associated with depressive symptoms, and heart rate and heart rate variability were associated with acute stress. Studies were limited with long-term observations (eg, ≥12 months) and large sample sizes, with limited integration of wearable data with system-level information (eg, acuity) to predict burnout. Reporting standards were also insufficient, particularly in device adherence and sampling frequency used for physiological measurements. CONCLUSIONS With wearables offering promise for digital health assessments of human functioning, it is possible to see wearables as a frontier for predicting burnout. Future digital health studies exploring the utility of wearable technologies for burnout prediction should address the limitations of data standardization and strategies to improve adherence and inclusivity in study participation.

1 December 2025 in JAACAP Open
Verified
Journal Article
Open access
MBMilica Barac
Milica Barac
PNPaul A. Nakonezny
Paul A. Nakonezny
PCPaul Croarkin
Paul Croarkin
AAArjun Athreya
Arjun Athreya
SJSophia M. Jones
Sophia M. Jones
GEGraham J. Emslie
Graham J. Emslie
Brief adaptations of existing rating scales may have advantages for research and clinical practice. This study examined the relative performance and psychometric properties of the 5-item Brief Children’s Depression Rating Scale–Revised (BCDRS-R5) in the context of a placebo-controlled clinical trial. The present study evaluated the internal consistency, scale dimensionality, relative performance in identifying remission and response, and sensitivity to change of the BCDRS-R5 in outpatients (N = 296) 12 to 17 years of age with major depressive disorder enrolled in a randomized, double-blind, placebo-controlled parallel group trial of the selegiline transdermal patch. The Cronbach coefficient alpha of the BCDRS-R5 ranged from 0.679 at baseline to 0.866 at week 12. A 1-factor solution for the BCDRS-R5 is suggested by the principal component analysis. The BCDRS-R5 demonstrated good accuracy in detecting response and remission. The BCDRS-R5 has good performance and is sensitive to change in symptom severity over 12 weeks of treatment, with either medication or placebo, when compared with the longer, standard CDRS-R17. Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression; https://clinicaltrials.gov/study/NCT00531947 We actively worked to promote sex and gender balance in our author group. We actively worked to promote inclusion of historically underrepresented racial and/or ethnic groups in science in our author group. While citing references scientifically relevant for this work, we also actively worked to promote sex and gender balance in our reference list. While citing references scientifically relevant for this work, we also actively worked to promote inclusion of historically underrepresented racial and/or ethnic groups in science in our reference list.